Kirby Institute

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1986-01-01

Employees: 101

Market Cap: -

Website: https://kirby.unsw.edu.au

Clinical Trials

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

Not Applicable

Completed

Conditions: Hepatitis C

Interventions: Device: HCV RNA Point of Care
Drug: Sofosbuvir/velpatasvir
Drug: Glecaprevir/pibrentasvir

First Posted Date: 2018-04-10

Last Posted Date: 2023-01-17

Lead Sponsor: Kirby Institute

Target Recruit Count: 101

Registration Number: NCT03492112

Locations: 🇦🇺
NUAA NSP, Sydney, New South Wales, Australia

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia

Interventions: Drug: CC-486
Drug: Azacitidine

First Posted Date: 2018-04-10

Last Posted Date: 2024-05-28

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT03493646

Locations: 🇦🇺
St George Hospital, Sydney, New South Wales, Australia
🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia

and more 8 locations

Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings

Completed

Conditions: Hepatitis C, Chronic

First Posted Date: 2017-11-17

Last Posted Date: 2022-04-14

Lead Sponsor: Kirby Institute

Target Recruit Count: 140

Registration Number: NCT03343925

Locations: 🇦🇺
Drug and Alcohol Services (Hunter), Newcastle, New South Wales, Australia
🇦🇺
Infectious Diseases Clinic, Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia

and more 1 locations

Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial

Phase 3

Completed

Conditions: HIV Prevention

Interventions: Drug: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)

First Posted Date: 2017-10-31

Last Posted Date: 2020-09-04

Lead Sponsor: Kirby Institute

Target Recruit Count: 900

Registration Number: NCT03327155

Locations: 🇦🇺
South Terrace Sexual Health Clinic, Fremantle, Western Australia, Australia
🇦🇺
Royal Perth Hospital Sexual Health Clinic, Perth, Western Australia, Australia
🇦🇺
GP on Beaufort, Mount Lawley, Western Australia, Australia

and more 1 locations

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Phase 3

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: glecaprevir (300mg)/pibrentasvir (120mg)

First Posted Date: 2017-04-18

Last Posted Date: 2019-12-11

Lead Sponsor: Kirby Institute

Target Recruit Count: 380

Registration Number: NCT03117569

Locations: 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇨🇦
William Osler Health System, Brampton, Ontario, Canada
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 30 locations

Study of Pomalidomide in Anal Cancer Precursors

Phase 2

Conditions: High Grade Squamous Intra-epithelial Lesion (HSIL)

Interventions: Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst]

First Posted Date: 2017-04-14

Last Posted Date: 2022-03-31

Lead Sponsor: Kirby Institute

Target Recruit Count: 26

Registration Number: NCT03113942

Locations: 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Phase 4

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: NRTIs
Drug: Dolutegravir
Drug: Darunavir
Drug: Ritonavir

First Posted Date: 2017-01-11

Last Posted Date: 2023-04-18

Lead Sponsor: Kirby Institute

Target Recruit Count: 831

Registration Number: NCT03017872

Locations: 🇦🇷
Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷
Hospital Dr Diego Paroissien, Isidro Casanova, Provincia De Buenos Aires, Argentina
🇦🇷
CAICI, Rosario, Provincia De Santa Fe, Argentina

and more 25 locations

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

Phase 4

Terminated

Conditions: Hepatitis C

Interventions: Drug: Grazoprevir/elbasvir

First Posted Date: 2016-10-21

Last Posted Date: 2020-03-09

Lead Sponsor: Kirby Institute

Target Recruit Count: 32

Registration Number: NCT02940691

Locations: 🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia
🇦🇺
Drug and Alcohol Clinical Services (Hunter), Newcastle, New South Wales, Australia
🇦🇺
Kirketon Road Centre, Darlinghurst, New South Wales, Australia

and more 2 locations

Expanded PrEP Implementation in Communities in NSW

Phase 3

Completed

Conditions: HIV
STI

Interventions: Drug: TDF/FTC

First Posted Date: 2016-08-17

Last Posted Date: 2021-02-17

Lead Sponsor: Kirby Institute

Target Recruit Count: 9733

Registration Number: NCT02870790

Locations: 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
🇦🇺
RPA Sexual Health, Camperdown, New South Wales, Australia
🇦🇺
St Leonards Medical Centre, North Sydney, New South Wales, Australia

and more 28 locations

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients

Terminated

Conditions: HIV-1 Infection

First Posted Date: 2016-04-08

Last Posted Date: 2021-11-08

Lead Sponsor: Kirby Institute

Target Recruit Count: 5

Registration Number: NCT02732457

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy